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The discovery of the size and complexity of the human microbiome has resulted in an ongoing reevaluation of many concepts of health
and disease, including diseases affecting the CNS. A growing body of preclinical literature has demonstrated bidirectional signaling
between thebrain and the gutmicrobiome, involvingmultiple neurocrine and endocrine signalingmechanisms.While psychological and
physical stressors can affect the composition andmetabolic activity of the gut microbiota, experimental changes to the gut microbiome
can affect emotional behavior and related brain systems. These findings have resulted in speculation that alterations in the gut micro-
biomemayplay apathophysiological role inhumanbraindiseases, includingautismspectrumdisorder, anxiety, depression, andchronic
pain. Ongoing large-scale population-based studies of the gut microbiome and brain imaging studies looking at the effect of gut micro-
biomemodulation on brain responses to emotion-related stimuli are seeking to validate these speculations. This article is a summary of
emerging topics covered in a symposium and is not meant to be a comprehensive review of the subject.
Introduction
Traditionally, microorganisms have not been considered of par-
ticular importance to the development and function of the CNS
or in the pathophysiology of chronic brain diseases, such as dis-
orders of mood and affect, Parkinson’s disease, or Alzheimer’s
disease. The often quoted and remarkable ability of the parasite
Toxoplasmosis gondii of hijacking the host’s (e.g., rat) brain sys-
tems related to defensive behaviors and sexual attraction to ma-
nipulate the rat’s behavior in a way that optimizes reproduction
of the parasite (House et al., 2011) was considered an interesting
outlier in the prevalent dogma of looking exclusively at the brain
for causes of behavior and brain diseases. One exception to the
traditional view has been autism spectrum disorder (ASD), a
brain disease that has long been suspected to be related to altered
gut microbiota (Mayer et al., 2014a), a concept that has recently
been revisited both in rodent models and in human subjects. The
“microbiome-free” worldview of neuroscience has dramatically
changed with the discovery and characterization of the human
microbiome and, in particular, with the gut microbiome (Hu-
man Microbiome Project Consortium, 2012). Although gut-
brain interactions have been studied for decades, providing a
wealth of information about the close interactions between the
gut-associated immune system, enteric nervous system, and gut-
based endocrine system (Mayer, 2011), these findings have
largely been ignored by the psychiatric and neurological research
community. The discovery of the gut microbiome has added a
long overlooked component to the complex bidirectional signal-
ing between mind, brain, gut, and its microbiome and surpris-
ingly has triggered a tremendous interest by the professional and
lay media, as well as by national funding agencies, including the
National Institute of Mental Health. The initial skepticism about
reports suggesting a profound role of an intact gut microbiota
in shaping brain neurochemistry and emotional behavior has
given way to an unprecedented paradigm shift in the conceptu-
alization ofmany psychiatric andneurological diseases. Although
many of the new concepts are primarily based on the intriguing
experimental findings in rodents, initial studies in humans seem
to support the notion that there is a relationship between the
complex world of microbiota in our intestines and brain struc-
ture and function. Even though themajority of published studies
of gut microbiome to brain signaling are based on microbiome
analyses from stool samples, future studies will almost certainly
expand the scope of investigations to mucosal samples taken
from different regions of the gastrointestinal tract. Based on our
current, still limited knowledge about these gut-microbiome-
brain interactions, intriguing speculations have been proposed in
a rapidly increasing number of review articles on the topic. They
range from terms, such as “psychobiotic” or “melancholic” mi-
crobes (Cryan andDinan, 2012), to concepts that humans are just
the vehicle for the 100 trillionmicroorganisms living inside of us.
The latter concept has been developed into the intriguing hy-
pothesis that the gut microbiota have developed ways to “hack”
into our reward system to make us crave certain foods and avoid
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others that are most beneficial to them (Alcock et al., 2014) Sim-
ilarly, microbe-brain interactions have been recently proposed to
be a key driver of the evolution of the social brain (Stilling et al.,
2014b). The following review addresses some aspects of the rap-
idly evolving topic of gut-microbiome-brain interactions in
health and disease (Fig. 1). Even though not a comprehensive
review of the topic, it provides a glance into this emerging new
view of neuroscience.
Gut microbiota regulates stress, anxiety, and cognition:
mechanisms and therapeutic potential
Accumulating evidence, largely from animal studies, suggests
that different types of psychological stress can affect the composi-
tion of the gut microbiota. For example, maternal separation, re-
straint conditions, crowding, heat stress, and acoustic stress all
alter the composition of the gutmicrobiota (Bailey et al., 2011;De
Palma et al., 2014; Moloney et al., 2014). In addition, a growing
body of data suggests that the microbiota may be involved in con-
trolling behaviors relevant to stress-related disorders.
Several experimental conditions have been used to study the
role of the gut microbiota in preclinical models, including
perturbation of the gut microbiome by
ingestion of probiotics and antibiotics,
fecal microbial transplant, and compar-
ison of behaviors and biological read-
outs between germ-free animals (raised
in a sterile environment from the time
of birth) and those with a pathogen-free
microbiome.
Germ-free animals
It is now a decade since Sudo et al. (2004)
discovered that germ-free mice have
an exaggerated hypothalamic-pituitary-
adrenal axis response to restraint stress, an
effect that was reversed bymonocoloniza-
tionwith a particularBifidobacterium spe-
cies. This seminal observationmotivated a
number of research groups to investigate
the role of the host gutmicrobiota onCNS
function, with converging and intriguing
results. Despite exaggerated neuroendo-
crine responses to stress, consistent re-
ductions in anxiety-like behavior were
observed in germ-free mice exposed to
more ecologically relevant stressors, such
as novel and aversive environments (ele-
vated plus maze, light/dark box, open
field) (Diaz Heijtz et al., 2011; Neufeld et
al., 2011; Clarke et al., 2013). This pheno-
type was susceptible to reversal when ani-
mals were colonized early in life (Clarke et
al., 2013). Interestingly, recent studies in
germ-free animals in the stress-sensitive
F344 rat strain showed similar exagger-
ated neuroendocrine responses but also
revealed an increase in anxiety-like behav-
ior (Crumeyrolle-Arias et al., 2014).
Moreover, it has recently been shown that
short-term colonization of germ-free
mice in adulthood reduced anxiety-like
behaviors (Nishino et al., 2013). Together,
it is clear that studies in germ-free animals
clearly show a relationship between gut
microbiota and stress and anxiety-related behaviors, the nature
of this relationship being influenced by temporal, sex, strain, and
species factors that are not yet fully understood.
A growing number of studies are also investigating gene ex-
pression changes in different brain regions in germ-free mice.
Most commonly, decreases in the hippocampal expression of
BDNF, a key protein involved in neuronal plasticity and cogni-
tion, have been observed in germ-free mice relative to conven-
tionally raised or conventionalized (i.e., initially germ-free mice
colonized with the normal mouse gut microbiota) controls. Sim-
ilar changes in BDNF expression have also been reported follow-
ing antibiotic administration (Bercik et al., 2011b). Alterations in
neurotransmitter signaling, including neurotransmitters and as-
sociated metabolites and neurotransmitter receptors, have also
been described in specific brain regions of germ-free mice. Diaz
Heijtz et al. (2011) took a genome-wide transcriptomic approach
showing that genes associated with the citrate cycle (synaptic
long-term potentiation, steroid hormonemetabolism, and cyclic
adenosine 5-phosphate-mediated signaling) were upregulated in
germ-free mice. Interestingly, in these studies, the cerebellum
Figure1. Bidirectional communication channels between the gutmicrobiome, the gut, and the brain. Endocrine-, neurocrine-,
and inflammation-related signals generated by the gutmicrobiota and specialized cells within the gut can, in principal, affect the
brain. In turn, the brain can influence microbial composition and function via endocrine and neural mechanisms.
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and hippocampus have robust changes in gene expression, but
the hypothalamus, the brain region involved in the stress re-
sponse, showed almost no differential gene expression.
Some behavioral and biochemical parameters (including anx-
iety, sociability, hypothalamic-pituitary-adrenal axis, and trypto-
phan metabolism) could be reversed in germ-free mice by
recolonizationwith a conventionalmicrobiota or probiotic treat-
ment, but others were unaffected by restoration of a normal mi-
crobiota (including 5-HT concentration and social cognition)
(Stilling et al., 2014a). Indeed, it has been thought that reversibil-
ity of the anxiolytic phenotype in germ-free mice is only guaran-
teed if recolonization happens during a critical time window
during early-life/adolescence (Neufeld et al., 2011; Clarke et al.,
2013). This has recently been challenged with evidence that adult
colonization affects anxiety-like behaviors (Collins et al., 2013;
Nishino et al., 2013).
It is important to note that the clinical translatability of germ-
free studies is limited. Early life antibiotic administration in ro-
dents does not recapitulate many of the behavioral germ-free
phenotypes (O’Mahony et al., 2014). One factor contributing to
this limited translational relevance is the fact that germ-free ani-
mals exhibit major alterations in gastrointestinal function, in-
cluding gross dilation of the proximal colon and alterations in
motility, and in the immune system, which presumably also has
important effects on the brain.Nonetheless, germ-free studies are
powerful in that they test definitively whether the microbiota is
involved in a specific aspect of brain function. Germ-free mice
also enable the study of the impact of a particular bacterial or
dietary intervention on the microbiota-gut-brain axis in isola-
tion. Studies in germ-free mice can also be expanded to enable
research on the “humanization” of the gutmicrobiota (i.e., trans-
planting fecal microbiota from specific human conditions or
from animal models of disease). In this regard, intriguing studies
have shown that the transplantation of microbiota from a high-
anxiety mouse strain to a germ-free low-anxiety recipient in
adulthood was sufficient to increase anxiety in the recipient, and
the converse was also true (Collins et al., 2013). These studies also
support the concept that the behavior of germ-free animals is
susceptible to alteration even into adulthood. Further evidence of
the microbial-based transferability of behavior comes from re-
cent studywherebymice, whose baselinemicrobiotawere ablated
with antibiotics, were given the microbiota from donor animals
that had been fed a high-fat diet. These mice had selective disrup-
tions in exploratory, cognitive, and stereotypical behavior compared
with mice transplanted with control microbiota in the absence of
significant differences in body weight (Bruce-Keller et al., 2014).
Probiotics
A growing body of evidence from rodent studies further supports
a role of the gut microbiome in modulating emotional behavior.
In animal models, a range of probiotics have been investigated.
Bifidobacterium and Lactobacillus are the main genera showing
beneficial effects on anxiety- and depression-like behavior. How-
ever, even within bacterial genera, marked strain differences
occur, and only a few strains have any positive effects (Dinan et
al., 2013). Chronic treatment with Bifidobacterium infantis
attenuated early-life stress-induced immune changes and
depressive-like behaviors in adulthood (Desbonnet et al.,
2010). Lactobacillus helveticus ROO52 has also been shown to
reduce anxiety-like behavior and alleviate memory dysfunction
(Ohland et al., 2013). Lactobacillus rhamnosus JB-1 reduced
anxiety- and depression-related behaviors in the elevated plus
maze and forced swim test, respectively (Bravo et al., 2011). Re-
cent work by Matthews and Jenks (2013) demonstrated reduced
anxiety and improved performance on a complex maze task
after treatment with live Mycobacterium vaccae. Bifidobacte-
rium longum normalizes anxiety-like behavior in a colitis model
(Bercik et al., 2011a). Furthermore, a B. longum, but not L. rham-
nosus strain, normalized infection-induced anxiety-like behavior
(Bercik et al., 2010). A combination of L. rhamnosus and L. hel-
veticus reversed stress-induced memory dysfunction in Citrobac-
ter rodentium-infected mice (Gareau et al., 2011). More recently,
it has been shown that VSL#3 (a mixture of eight different pro-
biotics) was able to reverse age- associated deficits in long-term
potentiation, the electrophysiological correlate of memory for-
mation (Distrutti et al., 2014). Probiotic treatment has also
proved efficacious in alleviating visceral pain responses in animal
models (Rousseaux et al., 2007; McKernan et al., 2010). Another
potential strategy for modulating the microbiome-gut-brain axis
is the use of prebiotics, nondigestible food ingredients that pro-
mote the growth of beneficial gut microorganisms (probiotics).
Surprisingly, there has been a paucity of studies in animals or
humans with prebiotics, although specific prebiotics have been
shown to increase brain BDNF levels (Savignac et al., 2013).
Overall, accumulating evidence in rodent studies suggests that
there are links among the microbiota composition, brain bio-
chemistry, and behavior and that these interactions may be par-
ticularly important at critical neurodevelopmental windows
(Borre et al., 2014). The underlying molecular mechanisms lead-
ing to these behavioral and biochemical alterations are not well
understood. Bacterial metabolites include many neuroactive
agents (Lyte, 2013; Wall et al., 2014), and understanding the spe-
cific components of themicrobial metabolome will be important
for understanding the role of themicrobiome in brain health and
disease (Holmes et al., 2012). Interestingly, there is now a grow-
ing appreciation of the role of epigenetic mechanisms in shaping
brain and behavior, and it is worth noting that many bacterial
metabolites can act as epigenetic modifiers (Stilling et al., 2014a).
Evidence for alterations in gut-microbiome-brain
interactions in a rodent model of ASD
Alterations in the communication between the gut microbiome
and the brain, including alterations in the composition and met-
abolic products of the gut microbiome, have been implicated in
the complex pathophysiology of ASD. Gastrointestinal symp-
toms are a common comorbidity in ASD patients, even though
the underlyingmechanisms are largely unknown. Several types of
rodentmodels for humanASDhave been proposed: (1) naturally
occurring rodent strains that demonstrate ASD-relevant behav-
ioral traits; (2) models expressing a human genetic mutation as-
sociated with ASD; and (3) models with acquired behaviors
resulting from various environmental insults either affecting the
developing animal directly (Desbonnet et al., 2014; de Theije et
al., 2014) or affecting the mother of ASD offspring. In one such
prenatally induced model, exposure of pregnant mice treated
with valproic acid resulted in ASD-like behavior in the offspring,
which were associated with alterations in the gut microbiome
associated with inflammatory and endocrine changes in both in-
testinal tract and in the nervous system.
Further linking the microbiota to ASD, germ-free mice
showed reduced sociability and have social cognition deficits in
the three-chamber test and exhibited increased repetitive groom-
ing behavior compared with their conventional counterparts
(Desbonnet et al., 2014). Interestingly, the deficits in sociability
and repetitive behaviors, but not social cognition, were reversed
by postweaning colonization. Recent provocative studies point to
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the ability of a Bacteroides fragilis strain given in early postwean-
ing life to reverse gastrointestinal, microbiota, and selective be-
havioral changes induced in a prenatal infection model of
neurodevelopmental disorders, such as ASD and schizophrenia
(Hsiao et al., 2013).
Overall, there is intriguing preclinical and some clinical evi-
dence to implicate alterations of the gut microbiome in the
pathophysiology of ASD. However, it remains to be determined
whether the observed microbiota changes are secondary to al-
tered neural (CNS, enteric nervous system) regulation of key gut
functions (motility, secretion), or if they represent primary pe-
ripheral alterations that affect brain development and function
(Mayer et al., 2014a). As ASD is a heterogeneous group of disor-
ders, it is unlikely that one diseasemechanism (such as altered gut
microbiota to brain signaling) applies to all disease phenotypes.
Gut-microbiome signaling in humans
Although our ability to study gut-microbiome-brain interactions
is more limited in humans than it is in preclinical models, it is
possible to obtain a broad view of the gut microbiota composi-
tion and metabolites by analysis of fecal samples and aim to cor-
relate such findings with brain activity and structure using
neuroimaging (Tillisch and Labus, 2014). Further,modulation of
the gastrointestinal microbiota in humans via foods, supple-
ments (including probiotics and prebiotics), or medications
(including antibiotics) can be used as experimental probes for
more mechanistic studies of brain-gut microbiome interactions
(Mayer et al., 2014b).
Modulation of the gut-brain axis with antibiotics
Manipulation of gut bacteria by antibiotics is used clinically to
improve brain function in hepatic encephalopathy, a complica-
tion of chronic liver disease (Butterworth, 2013). Patients with
hepatic encephalopathy have variable alterations in cognitive
function, presumably due to gut microbial metabolites that are
not efficiently cleared by the diseased liver. In patients with mild
hepatic encephalopathy, 8 weeks of oral treatment with a nonab-
sorbable antibiotic was associated with improvements in cogni-
tive function based on a battery of standardized tests (Bajaj et al.,
2013). These cognitive changes occurred in the absence of major
changes in the overall microbiome composition by principal
component analysis. However, metabolomic changes were de-
tected in the serum. Short-chain fatty acids, a major metabolic
product of the gut microbiota with well-known effects on the
nervous system, were increased (Haast and Kiliaan, 2014). The
authors hypothesized that the changes in profiles of fatty acids in
the peripherymay correspond tomore favorable profiles of brain
fatty acids, as amechanism for improved cognition. Treatment of
hepatic encephalopathy with the same antibiotic in an open label
study was associated with altered functional connectivity during
a cognitive task and changes in white matter integrity (as mea-
sured by fractional anisotropy) (Ahluwalia et al., 2014). These
changes support previous work in animal models, in which anti-
biotic treatment has been associated with both behavioral
changes and changes in neurochemistry (Bercik et al., 2011b).
Surprisingly, despite the widespread use of antibiotics and clini-
cal descriptions of cognitive and psychiatric side effects, little
evaluation of the role of antibiotics in the human microbiome-
brain axis has taken place (Sternbach and State, 1997; Tome´ and
Filipe, 2011).
Modulation of the gut-brain axis with probiotics
Probiotics are used widely; and as consumer products, they rep-
resent a20 billion dollar industry worldwide. However, despite
many unsubstantiated claims, probiotic effects on the structure
and function of the human gut microbiota have been studied in
only a few specific strains, and our understanding of their effects
on clinical symptoms is far from complete (Sanders et al., 2013).
Several probiotics have been shown to have utility for specific
gastrointestinal and global symptoms in irritable bowel syn-
drome, a chronic pain condition characterized by dysregulation
of the brain-gut axis (Moayyedi et al., 2010; Mayer et al., 2014b).
Whether these benefits are due primarily to peripheral actions
in the gut or due to central effects is not known. In chronic
fatigue syndrome, another disorder of brain–body interac-
tions, a randomized, double-blind, placebo-controlled trial of
a Lactobacillus-containing probiotic decreased anxiety, but not
depression symptoms, in the active treatment group, and in-
creased the relative abundance ofBifidobacterium and Lactobacil-
lus in the stool (Rao et al., 2009). This study, published as a brief
report, lacked detail in terms of the reported results, thus should
be interpreted with caution. Two small studies of probiotics ef-
fects on mood and cognition in healthy individuals have been
published, both of which suggest an effect on the microbiome
brain axis. In the first, a Lactobacillius- and Bifidobacterium-
containing probiotic was compared with placebo in healthy vol-
unteers, measuring mood symptoms with the Hospital Anxiety
and Depression Scale. The percentage decrease in the total Hos-
pital Anxiety and Depression Scale score was greater in the pro-
biotic group, but not in the subscales (Messaoudi et al., 2011). A
reduction in urinary-free cortisol was also seen over the course of
the treatment in the probiotic group, but not the placebo group,
although the group difference was not significant. In this study,
the authors ran an experimental arm of probiotic treatment in
rodents, and consistent with the human results, saw improved
behavioral performance in an anxiety-like task. In the second
study, the effects of a Lactobacillus containing dairy drink were
compared with placebo, with no significant group changes in
mood, as measured by the Profile of Mood States (Benton et al.,
2007). The authors suggest that this lack of effect may have been
due to the overall positive mood of the sample, and did note a
small effect when looking at a post hoc small subgroup of subjects
at the lowest tertile of mood states. Surprisingly, this same study
showed diminished memory scores in the probiotic groups ver-
sus the placebo group. Although these studies overall suggest a
potential for positive effects of some probiotics on mood, clearly
larger, well-designed clinical trials, ideally with biological as well
as self-report outcomes in patient populations, are needed to
make clear conclusions.
Imaging of the brain in gut-microbiome-brain interactions
Although they are important from a mechanistic standpoint,
most preclinical studies have used nonphysiological experimen-
tal interventions (e.g., germ-free animals), simplified constructs
of complex human emotions (anxiety and depression), and are
often based on erroneous assumptions about the anatomical and
functional homology of the rodent and human brains (in partic-
ular the prefrontal cortex and the anterior insula). Therefore, it is
currently unclear what the translational value of the results ob-
tained in these rodent models for understanding brain or brain-
gut disorders in humans will be. Clearly, more studies in humans
are needed to verify some of the intriguing animal findings. fMRI
can be used in humans to observe changes in brain response after
a probiotic or antibiotic interventions, just as it is commonly used
to test pharmaceuticals or behavioral interventions (Mayer et al.,
2002; Wise and Tracey, 2006; Tillisch et al., 2008). The effect of
daily probiotic intake on brain responses to an emotion recogni-
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tion task have been described in healthy women (Tillisch et al.,
2013). In this study, women without any gastrointestinal symp-
toms, pain, or psychiatric disorderwere randomized to treatment
with a probiotic, a nonfermented dairy product or no treatment.
The response to negative affect faces in an emotional recognition
task was measured with fMRI before and after the treatment pe-
riod. Compared with both control groups, the probiotic group
showed reductions in response to the task in the insula and so-
matosensory cortices specifically, as well as across a widespread
functional network, including emotional and sensory regions.
Although alternative interpretations are possible, these findings
may represent a reduction in vigilance to negative environmental
stimuli in subjects who regular consume probiotics. The changes
in brain activity were independent of self-reported gastrointesti-
nal symptoms, indicating that the central effect was not likely due
to an improved sense of digestive well-being. Confirming results
from a previous study with detailed microbial andmetabolomics
analyses (McNulty et al., 2011), no group-specific changes in the
overall architecture of themicrobiotawere observed after 4weeks
of probiotic ingestion, although stool samples did provide con-
firmation that the specific probiotic strains were present in the
treatment group. This is consistent with the hypothesis that, at
least in the short term, microbial metabolites rather than overall
microbial configuration may be the salient result of probiotic
ingestion (McNulty et al., 2011). Functional and structural neu-
roimaging, along with metabolomic and metagenomic measure-
ments from stool, will be essential in providing a better
understanding of how the gut-microbiome-brain axis functions
in human health and disease.
Multilevel data integration of brain andmicrobiome-
related data
Advances in computational approaches are urgently needed to
better understand links between the gut microbiota and the
brain.Of particular importance are tools to integrate large, highly
multivariate datasets (Gonzalez and Knight, 2012; Navas-Molina
et al., 2013). These datasets include taxonomic profiles obtained
from 16S rRNA amplicon sequencing or shotgunmetagenomics,
gene catalogs from shotgun metagenomics, expression datasets
frommRNA sequencing or proteomics, metabolite profiles from
targeted or untargeted metabolomics, behavioral datasets, and
imaging data, including structural and fMRI. Increasingly, these
datasets also involve time series components, especially as the
data acquisition methods decrease in cost (for example, 16S
rRNA amplicon profiling has decreased in cost by almost a factor
of amillion over the past decade) (Kuczynski et al., 2012). As data
analysis techniques in each of these areas individually are evolv-
ing rapidly, integrating them is even more of a moving target.
Many microbiome-brain links may have been overlooked be-
cause other causal pathways seemed initially more plausible. For
example, TLR5 knock-out mice, in certain facilities, gain weight
with respect to wild-type mice on the same diet and develop
metabolic syndrome. This effect disappears when the mice are
raised germ-free, and can be treated with antibiotics. Fascinat-
ingly, the mechanism is behavioral: in obesogenic environments,
the TLR5 knock-out mice have an altered microbial community
that can be transmitted even to genetically normalwild-typemice
that are raised germ-free. This altered microbial community in-
duces a change in ingestive behavior (e.g., hyperphagy: obesity
can be prevented and reversed by placing in the cage only the
amount of food a wild-type mouse would eat) (Vijay-Kumar et
al., 2010). Although the mechanism of this effect remains un-
known, particular species of bacteria in the gut are known to
affect the levels of appetite-regulating hormones, including leptin
(Ravussin et al., 2012) and ghrelin (Queipo-Ortun˜o et al., 2013).
Similarly, probiotic effects of L. rhamnosis on host GABA recep-
tor expression require an intact vagus nerve (Bravo et al., 2011).
The potential for many other microbially induced phenotypes to
act via behavioralmechanisms, including neural signaling, is thus
immense and at present underexplored.
Tools for tracking the dynamics of themicrobiome are rapidly
evolving (Caporaso et al., 2011; Va´zquez-Baeza et al., 2013) and
provide insights both into normalmicrobiome variation and into
its changes in responses to therapy, including antibiotics (Lo-
zupone et al., 2013) and fecal microbiota transplant (Khoruts A,
SadowskyM, University of Minnesota, unpublished data). These
tools can easily be extended to other multivariate datasets, in-
cluding features derived from imaging datasets, through use of
the Biological Observation Matrix file format (McDonald et al.,
2012). Essentially, the technique is to use a large population, such
as the HumanMicrobiome Project Consortium (2012), as a data
frame, then project the time series corresponding to one or more
individuals as animations in that data frame, also recording de-
rived features, such as the variability over time, the direction of
change in the multivariate space, etc. (Carvalho et al., 2012).
The American Gut Project
An especially exciting opportunity is provided by the American
Gut Project, which uses crowd sourcing (obtaining samples
and/or assistance with data analysis frommembers of the general
public) and crowd funding (obtaining financial support from
members of the general public) to obtain thousands of fecal (and
other) samples, and analyze the bacterial communities contained
in those samples. Several studies have shown that storage of un-
fixed samples at room temperature do not alter the major micro-
biological conclusions (e.g., clustering of samples from the same
subject together) (Lauber et al., 2010; Wu et al., 2010). Although
there are differences between the stool microbiota and other sites
in the distal large intestine in the same subject, these differences
are smaller than the differences between subjects, and so, provide
a good readout of the distal large intestine (although note that the
small intestine differs substantially in its microbiology) (Eckburg
et al., 2005; Hamady and Knight, 2009; Gevers et al., 2014). As of
this writing, American Gut has publicly released sequence data
from almost 4000 microbial samples from members of the gen-
eral public. Excitingly, this dataset easily allows us to integrate
information from clinical populations, and specialized studies
are underway in depression, ASD, and irritable bowel syndrome
and celiac disease (both of which have substantial comorbidity
with depression), multiple sclerosis, and other conditions affect-
ing the nervous system in which microbes are either known to be
involved in humans, are involved in mouse models or where
plausible, though speculative, pathways exist. Especially, the
availability of methods to correlate different kinds of data, and to
integrate detailed time-series, including cycles of remission and
relapse or the effects of specific treatments, provide substantial
hope for identifying new ways of stratifying patients and new
treatment modalities.
In conclusion, the discovery and the explosive progress in the
characterization of the gutmicrobiome have initiated a paradigm
shift not only in medicine, but also in the basic and clinical do-
mains of neuroscience. To understand themagnitude of this par-
adigm shift, the reader has to be reminded of the powerful grip of
Descartes’ separation of mind/brain on the one side (religion,
psychiatry) and body on the other side (medicine) that has dom-
inated Western science and medicine for hundreds of years. Not
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only is the concept of gut-microbiome-brain interactions in
health and disease paradigm breaking, the emerging data-driven,
analytical methodologies that are required to pursue the integra-
tion of massive amounts of data are equally revolutionary. It is
difficult to predict the trajectory of exciting period of discovery:
Will the gut microbiome add paradigm-transforming insights to
our existing understanding of human brain function in health
and disease, resulting in novel therapies, or will it represent an
incremental step in understanding the inner workings of our
brains? The next few years of research hold the potential of un-
covering intriguing connections between gut bacteria and neuro-
logical conditions that may possibly impact human health.
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